Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Atara Biotherapeutics (ATRA) Other Gross PP&E Adjustments (2021 - 2026)

Atara Biotherapeutics filings provide 6 years of Other Gross PP&E Adjustments readings, the most recent being -$6.9 million for Q1 2026.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 85.91% to -$6.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$6.9 million, a 85.91% increase, with the full-year FY2025 number at -$6.9 million, up 74.52% from a year prior.
  • Other Gross PP&E Adjustments hit -$6.9 million in Q1 2026 for Atara Biotherapeutics, roughly flat from -$6.9 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $427000.0 in Q1 2022 to a low of -$68.5 million in Q4 2022.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$32.3 million (2024), compared with a mean of -$32.3 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: plummeted 10879.86% in 2023 and later soared 85.91% in 2026.
  • Atara Biotherapeutics' Other Gross PP&E Adjustments stood at -$68.5 million in 2022, then grew by 28.11% to -$49.2 million in 2023, then surged by 45.18% to -$27.0 million in 2024, then soared by 74.52% to -$6.9 million in 2025, then dropped by 0.03% to -$6.9 million in 2026.
  • The last three reported values for Other Gross PP&E Adjustments were -$6.9 million (Q1 2026), -$6.9 million (Q4 2025), and -$10.2 million (Q3 2025) per Business Quant data.